Bragar Eagel & Squire, P.C Continues Investigations on Behalf of PetMed, GeneDx, Lineage, and Proficient Auto and Encourages Investors to Contact the Firm
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PetMed (PETS), GeneDx (WGS), Lineage (LINE), and Proficient Auto (PAL). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
PetMed Express, Inc. (NASDAQ: PETS)
On June 10, 2025, PetMed issued a press release 'announc[ing] it is delaying the release of the Company's fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process.'
On this news, PetMed's stock price fell $0.47 per share, or 11.22%, to close at $3.72 per share on June 11, 2025.
For more information on the SelectQuote investigation go to: https://bespc.com/cases/PETS
GeneDx Holdings Corp. (NASDAQ:WGS)
On February 5, 2025, Grizzly Research ('Grizzly') published a report entitled 'Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud'. The Grizzly report asserted, among other things, that GeneDx's 'growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue'; that '[t]estimonies from former employees and ongoing litigation suggest that GeneDx has inflated its revenue through an illegal practice known as 'code stacking'', which 'enables the company to bill insurance providers for services that do not meet the required criteria'; and that 'CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, without ever engaging in open market purchases', a 'pattern suggest[ing] that insiders may be aware of an imminent risk that will significantly impact the company.'
On this news, GeneDx's stock price fell $4.84 per share, or 6.72%, to close at $67.18 per share on February 5, 2025.
For more information on the Cleveland-Cliffs investigation go to: https://bespc.com/cases/WGS
Lineage, Inc. (NASDAQ:LINE)
On April 30, 2025, Lineage reported first quarter 2025 financial results, including that '[t]otal revenue decreased (2.7)%' to $1.29 billion for the quarter. The Company stated it 'experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels.'
On this news, Lineage's stock price fell $8.26, or 14.62%, to close at $48.23 per share on April 30, 2025, thereby injuring investors.
For more information on the Lineage investigation go to: https://bespc.com/cases/LINE
Proficient Auto Logistics, Inc. (NASDAQ:PAL)
On May 7, 2025, Proficient Auto announced financial results for its first quarter ended March 31, 2025, revealing that the Company had suffered a 0.4% year-over-year decrease in total operating revenue to $95.2 million and total operating loss of $2.4 million during the quarter.
On this news, Proficient Auto's stock price fell $0.40 per share, or 4.93%, to close at $7.72 per share on May 8, 2025.
For more information on the Semler investigation go to: https://bespc.com/cases/PAL
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Marion Passmore, Esq.(212) 355-4648
[email protected]
www.bespc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nordson (NDSN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Manufacturing company Nordson (NASDAQ:NDSN) will be reporting results this Wednesday afternoon. Here's what to look for. Nordson beat analysts' revenue expectations by 1.1% last quarter, reporting revenues of $682.9 million, up 5% year on year. It was a satisfactory quarter for the company, with EPS guidance for next quarter topping analysts' expectations but organic revenue in line with analysts' estimates. Is Nordson a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Nordson's revenue to grow 9.1% year on year to $721.7 million, improving from the 2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.63 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nordson has missed Wall Street's revenue estimates three times over the last two years. Looking at Nordson's peers in the professional tools and equipment segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lincoln Electric delivered year-on-year revenue growth of 6.6%, beating analysts' expectations by 5.1%, and Hillman reported revenues up 6.2%, topping estimates by 2.6%. Lincoln Electric traded up 7.8% following the results while Hillman was also up 22.9%. Read our full analysis of Lincoln Electric's results here and Hillman's results here. There has been positive sentiment among investors in the professional tools and equipment segment, with share prices up 4.8% on average over the last month. Nordson's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $251.80 (compared to the current share price of $215.93). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Analog Devices (ADI) Q2 Earnings: What To Expect
Manufacturer of analog chips Analog Devices (NASDAQ:ADI) will be reporting results this Wednesday before market hours. Here's what to look for. Analog Devices beat analysts' revenue expectations by 5.2% last quarter, reporting revenues of $2.64 billion, up 22.3% year on year. It was a very strong quarter for the company, with a beat of analysts' EPS estimates and an impressive beat of analysts' adjusted operating income estimates. Is Analog Devices a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Analog Devices's revenue to grow 19.5% year on year to $2.76 billion, a reversal from the 24.9% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.95 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Analog Devices has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average. Looking at Analog Devices's peers in the analog semiconductors segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Impinj's revenues decreased 4.5% year on year, beating analysts' expectations by 4.3%, and Universal Display reported revenues up 8.4%, topping estimates by 6.1%. Impinj traded up 26.2% following the results while Universal Display's stock price was unchanged. Read our full analysis of Impinj's results here and Universal Display's results here. Investors in the analog semiconductors segment have had steady hands going into earnings, with share prices flat over the last month. Analog Devices is down 3.5% during the same time and is heading into earnings with an average analyst price target of $254.16 (compared to the current share price of $232.10). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
2 hours ago
- Yahoo
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ('CytoMed' or 'Company'), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce that it entered into an At-the-Market Sales Agreement (the 'Sales Agreement') with R.F. Lafferty & Co., Inc. (the 'Agent'), as the sales agent. Pursuant to the Sales Agreement, the Company may offer and sell through the Agent, ordinary shares, no par value (the 'Shares'), of the Company having an aggregate value of up to U.S.$4,304,945. The timing and amount of any sales of Shares under the ATM program will be determined by the Company at its discretion, depending on market conditions and the Company's capital requirements. The Company intends to use the proceeds from the ATM program for general corporate purposes, which may include business diversification and development initiatives and capital expenditures. We may also use a portion of the net proceeds from this offering to appoint professionals to explore potential acquisitions or strategic investments in complementary businesses or technologies. However as of the date of this press release, the Company has not entered into any definitive agreements. The Company will provide updates to shareholders as additional information becomes available. In the event that any net proceeds are not immediately applied, we may temporarily hold them as cash or deposit them in banks. For information, the Company's newly acquired cord blood bank has seen approximately 2,500 new customer sign-ups since acquiring it in August 2024, contributing to revenue in 2025. About CytoMed Therapeutics Limited (CytoMed) Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit and follow us on Twitter ('X') @CytomedSG, on LinkedIn, and Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. Contact : CytoMed Therapeutics Limitedenquiry@ : Evelyn Tan, Chief Corporate Officer
